While a positive advisory committee meeting seemed to up the odds of approval for Replimune’s twice-snubbed melanoma drug in ...

About two years ago, a head-to-head progression-free survival win made Akeso and Summit Therapeutics’ ivonescimab—and the ...

Novartis is taking social media by storm with a multiple sclerosis (MS) campaign that urges patients to #KnowYourMS, a ...

Repatha, also known as evolocumab, was first approved by the FDA in 2015 to help patients lower their LDL, or “bad,” ...

Following a string of customer complaints, a Form 483 and a recall this past spring, a Fresenius manufacturing unit in Utah ...

CMI Media Group is adding to its spread of media services through a new specialty communications business that introduces a ...

Following a blow to the integrated contract developer and manufacturer’s client base, Cellares continues to move forward with ...

Since the launch of the Medicare GLP-1 Bridge on July 1, over 500,000 seniors have utilized the program and together saved ...

Novartis appears to have broken the curse of the BTK inhibitor class. | Novartis appears to have broken the curse of the BTK ...

Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top ...

Frontier Large Language Models have improved. More data became accessible. Neither solved the hardest questions. Here's what ...

For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...